Hypoxia, therapeutic resistance and sphingosine 1-phosphate - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Chapitre D'ouvrage Année : 2012

Hypoxia, therapeutic resistance and sphingosine 1-phosphate

Résumé

Hypoxia, defined as a poor oxygenation, has been long recognized as a hallmark of solid tumor and an negative prognostic factor for response to therapeutics and survival of patients. Cancer cells have evolved biochemical mechanisms that allow them to react and adapt to hypoxia. Ath the cellular level this adaptation is under the control of two related transcription factor, HIF-1 and HIF-2 (hypoxia-inducible factor), that respond rapidly to decreased levels to activate the expression of a broad range of genes promoting neoangiogenesis, glycolysis, metastasis, increased tumor growth and resistance to treatments. Recent studies have identifed the sphingosine kinase 1/sphingosis 1-phosphate (SphK1/S1P) signaling pathway - which elicits various cellular processes including cell proliferation cell survival or angiogenesis - as a new regulator of HIF-1 or HIF-2 activity. In this review, we will focus on how the inhibition-neutralization of the SphK1/S1Psignaling could be exploited for cancer therapy.
Fichier non déposé

Dates et versions

hal-00919085 , version 1 (16-12-2013)

Identifiants

  • HAL Id : hal-00919085 , version 1

Citer

Olivier Cuvillier, Isabelle Ader, Pierre Bouquerel, Leyre Brizuela, Cécile Gstalder, et al.. Hypoxia, therapeutic resistance and sphingosine 1-phosphate. Advances in Cancer Research, Academic Press, pp.117-141, 2012. ⟨hal-00919085⟩
30 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More